What is Juvenile Idiopathic Arthritis?
Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease of childhood, defined as arthritis beginning before 16 years of age, lasting for at least 6 weeks, and occurring without an identifiable cause (hence "idiopathic"). JIA is not a single disease but an umbrella term for 7 distinct subtypes, each with a different pattern of joint involvement, genetic background, associated features, and prognosis.
JIA is a serious condition that can permanently damage the growing joints and cause ocular complications (uveitis) that can lead to blindness if not detected and treated. The modern era of biologic therapy has transformed outcomes — children with JIA who are diagnosed early and treated aggressively can now achieve full remission, grow normally, and live full, healthy lives.
Swollen knee in a child with Oligoarticular JIA. Children often do not complain of pain but may limp or refuse to use the affected limb.
The 7 Subtypes of JIA
1. Oligoarticular JIA (most common – 50% of JIA)
Affects ≤4 joints in the first 6 months, predominantly large joints (knee, ankle). Predominantly affects young girls. High risk of asymptomatic anterior uveitis (ANA-positive patients) — regular slit-lamp examination is mandatory.
2. Polyarticular JIA – RF Negative
Affects ≥5 joints. Similar to oligoarticular in demographics. More joints at risk but generally responds well to treatment.
3. Polyarticular JIA – RF Positive
Resembles adult Rheumatoid Arthritis. Affects mostly teenage girls. Small joint involvement (hands, feet, wrists), rheumatoid nodules possible. Often a challenging, erosive course.
4. Systemic JIA (sJIA)
A unique, severe subtype with systemic features: daily quotidian fever (spiking to ≥39°C and returning to normal), a characteristic salmon-coloured evanescent rash, hepatosplenomegaly, lymphadenopathy, and serositis — in addition to arthritis. Risk of a life-threatening complication: Macrophage Activation Syndrome (MAS).
5. Psoriatic JIA
Arthritis associated with psoriasis, dactylitis, or nail pitting.
6. Enthesitis-Related Arthritis (ERA)
The paediatric equivalent of Spondyloarthropathy — enthesitis plus arthritis in HLA-B27 positive children, predominantly boys. Risk of evolving to Ankylosing Spondylitis in adulthood.
7. Undifferentiated JIA
Does not fit any of the above categories or fits more than one.
Slit-lamp examination — essential screening for silent uveitis in JIA. Anterior uveitis in JIA is often completely asymptomatic and can cause irreversible vision loss if missed.
👁️ Uveitis: The Silent Threat
Uveitis (eye inflammation) in JIA — particularly in young, ANA-positive, oligoarticular JIA girls — is often completely asymptomatic. The eye does not look red and does not hurt. Yet if untreated, it can cause cataracts, glaucoma, and permanent blindness. Mandatory slit-lamp screening every 3-6 months is critical for at-risk JIA children.
Dr. Prateek's Approach to JIA
Children deserve the very best of specialist rheumatological care. Dr. Prateek Deo brings the depth of knowledge needed to accurately subtype JIA, initiate appropriate therapy, coordinate with ophthalmology for uveitis surveillance, and guide families through the challenges of managing a chronic disease in a growing child.
Subtype-Specific Care
Each JIA subtype has a completely different treatment algorithm. We accurately subtype every child to ensure the correct medications are used from the outset.
Uveitis Coordination
We work closely with ophthalmologists to ensure mandatory, regular slit-lamp surveillance for at-risk children and prompt methotrexate or biologic treatment for eye disease.
Biologics for Children
We use paediatric-approved biologics (Etanercept, Adalimumab, Abatacept, Tocilizumab) where indicated — transforming outcomes for children with severe JIA.
MAS Vigilance
In systemic JIA, we maintain high vigilance for Macrophage Activation Syndrome — a potentially fatal complication — monitoring ferritin, liver enzymes, and CBC at each visit.